These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28050323)

  • 1. Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia.
    Aydoğan T; Erdoğan G; Ünlü C; Ergin A
    Turk J Ophthalmol; 2016 Dec; 46(6):270-273. PubMed ID: 28050323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
    Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
    Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
    Solaiman KA; Diab MM; Abo-Elenin M
    Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia.
    Roller AB; Folk JC; Patel NM; Boldt HC; Russell SR; Abramoff MD; Mahajan VB
    Retina; 2011 Oct; 31(9):1848-55. PubMed ID: 21610563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
    Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE
    Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion.
    Hung KH; Lee SM; Lee SY; Lee FL; Yang CS
    J Ocul Pharmacol Ther; 2010 Feb; 26(1):85-90. PubMed ID: 20148661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
    Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
    Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Intravitreal Bevacizumab in Treatment of Proliferative Type 2 Idiopathic Juxtafoveal Telangiectasia.
    Baz Ö; Yılmaz İ; Alagöz C; Demircan A; Perente İ; Özkaya A; Taşkapılı M
    Turk J Ophthalmol; 2017 Jun; 47(3):144-148. PubMed ID: 28630789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
    Arevalo JF; Sanchez JG; Wu L; Maia M; Alezzandrini AA; Brito M; Bonafonte S; Lujan S; Diaz-Llopis M; Restrepo N; Rodríguez FJ; Udaondo-Mirete P;
    Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema.
    Wang YS; Li X; Wang HY; Zhang ZF; Li MH; Su XN
    Chin Med J (Engl); 2011 Feb; 124(3):352-8. PubMed ID: 21362332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results.
    Arevalo JF; Maia M; Garcia-Amaris RA; Roca JA; Sanchez JG; Berrocal MH; Wu L;
    Ophthalmology; 2009 Aug; 116(8):1481-7, 1487.e1. PubMed ID: 19545901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia.
    Takayama K; Ooto S; Tamura H; Yamashiro K; Otani A; Tsujikawa A; Yoshimura N
    Eye (Lond); 2010 Sep; 24(9):1492-7. PubMed ID: 20431610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of bevacizumab in diabetic macular oedema in a 12-month follow-up.
    Jamrozy-Witkowska A; Grabska-Liberek I; Skonieczna K
    Klin Oczna; 2014; 116(4):237-41. PubMed ID: 25906633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab for myopic choroidal neovascularization: short-term and 1-year results.
    Spielberg L; Leys A
    Bull Soc Belge Ophtalmol; 2009; (312):17-27. PubMed ID: 19927486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.